Lubbock TX 多发性骨髓瘤临床试验
4项针对 多发性骨髓瘤的研究正在 Lubbock及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
招募中3 期
- Joe Arrington Cancer Research and Treatment Center, Lubbock
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
招募中3 期
- Joe Arrington Cancer Research Treatment Center, Lubbock
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
招募中4 期
- Texas Tech University Health Science Center School of Medicine, Lubbock
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
招募中3 期
- Joe Arrington Cancer Research Treatment Center, Lubbock
其他城市的 多发性骨髓瘤试验
- New York City, NY59 项研究
- Boston, MA45 项研究
- Atlanta, GA42 项研究
- Houston, TX39 项研究
- Durham, NC36 项研究
- Nashville, TN31 项研究
- Denver, CO26 项研究
- St. Louis, MO26 项研究
- Rochester, MN25 项研究
- Columbus, OH25 项研究
- Chicago, IL24 项研究
- Milwaukee, WI23 项研究
Lubbock的其他研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。